Oct 31 2014
BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, announced the online availability of an abstract providing preliminary data from the Q3W arm of its ongoing Phase 2 study of BIND-014 in non-small cell lung cancer (NSCLC).
Data included in the abstract were current as of the submission deadline on June 13, 2014 and updated data will be presented in a poster presentation on November 19, 2014 at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain. The abstract was published online at www.ecco-org.eu/ENA.
BIND-014 Poster at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
- Poster Title: Clinical activity of BIND-014 (docetaxel nanoparticles for injectable suspensions) as second-line therapy in patients (pts) with Stage III/IV non-small cell lung cancer
- Date: Wednesday, November 19, 2014 from 9 am - 7:30 pm CET
- Poster Session: Cytotoxics; Poster #035
About BIND-014
BIND-014, a targeted polymeric nanoparticle, represents the first Accurin nanomedicine from BIND’s Medicinal Nanoengineering® platform to reach the clinic. BIND-014 targets prostate-specific membrane antigen (PSMA), a target expressed on prostate cancer cells and the blood vessels of many types of non-prostate solid tumors, and contains docetaxel, a clinically-validated and widely used anti-cancer agent. In preclinical cancer models, BIND-014 was shown to increase accumulation of docetaxel at the site of disease which translated to marked improvements in antitumor activity and tolerability. In a phase 1 study, BIND-014 was generally well-tolerated and displayed anti-tumor activity at low doses and in tumors where conventional docetaxel has minimal activity. BIND-014 is currently in two Phase 2 studies in non-small cell lung cancer and metastatic castrate resistant prostate cancer.
About Accurins™
Accurins are BIND’s targeted and programmable therapeutics, which are designed, utilizing BIND’s medicinal nanoengineering platform, with specified physical and chemical characteristics to target specific cells or tissues and concentrate a therapeutic payload at the site of disease to enhance efficacy while minimizing adverse effects on healthy tissues. Accurins are polymeric nanoparticles that incorporate a therapeutic payload and are designed to have prolonged circulation within the bloodstream, enable targeting of the diseased tissue or cells, and provide for the controlled and timely release of the therapeutic payload. BIND has demonstrated in preclinical studies that Accurins can improve tumor growth suppression, achieve higher concentrations of the payload in tumors compared to the payload administered in conventional form, and have pharmacokinetics and tolerability differentiated from their therapeutic payloads.
About BIND Therapeutics
BIND Therapeutics is a clinical-stage nanomedicine platform company developing Accurins, its novel targeted therapeutics. BIND is leveraging its Medicinal Nanoengineering® platform to develop a pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. BIND’s lead drug candidate, BIND-014, is an Accurin that targets PSMA and contains docetaxel, a clinically-validated and widely used anti-cancer agent. BIND-014 is currently in Phase 2 clinical trials for the treatment of non-small cell lung cancer and metastatic castrate-resistant prostate cancer. BIND has announced ongoing collaborations with Pfizer Inc., AstraZeneca AB and F. Hoffmann-La Roche Ltd. to develop Accurins based on their proprietary therapeutic payloads and targeting ligands. BIND’s platform originated from the pioneering nanotechnology research at the Massachusetts Institute of Technology and Brigham and Women’s Hospital/Harvard Medical School of BIND’s scientific founders Dr. Robert Langer and Dr. Omid Farokhzad. For more information, please visit the Company's web site at www.bindtherapeutics.com.
Source: http://www.bindtherapeutics.com/